Case-Based Roundtable Meetings Spotlight: February 2, 2022

February 21, 2022

During a Targeted Oncology case-based roundtable event, John M. Pagel, MD, PhD, discusses the case of a patient with diffuse large B-cell lymphoma who is not eligible for transplant.

February 21, 2022

During a Targeted Oncology case-based roundtable event, Scott Tykodi, MD, PhD, discussed the data supporting various treatment options for renal cell carcinoma with participants.

February 20, 2022

During a Targeted Oncology case-based roundtable event, Ruben Mesa, MD, discussed risk assessment and management of myeloproliferative neoplasms.

February 19, 2022

During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.

February 18, 2022

During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.

February 18, 2022

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.

February 17, 2022

During a Targeted Oncology case-based roundtable event, Jennifer L. Atlas, MD, discussed the case of a patient with infiltrative basal cell carcinoma with participants.

February 17, 2022

During a Targeted Oncology case-based roundtable event, Rachel N. Grisham, MD, discussed clinical trials of different PARP inhibitors for patients with ovarian cancer.

February 16, 2022

During a Targeted Oncology case-based roundtable event, Uday R. Popat, MD, discussed the approaches to identifying and managing graft-vs-host disease.

February 16, 2022

During a Targeted Oncology case-based roundtable event, Roy S. Herbst, MD, PhD, and Joshua K. Sabari, MD, discussed molecular testing and the use of immune checkpoint inhibitors with participants.

February 15, 2022

During a Targeted Oncology live virtual event, Javier L. Munoz, MD, MBA, discussed third-line treatments for DLBCL including chimeric antigen receptor T-cell therapy and targeted treatments.